PMID- 37830618
OWN - NLM
STAT- MEDLINE
DCOM- 20231101
LR  - 20240501
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 12
IP  - 19
DP  - 2023 Oct 4
TI  - Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor 
      Immune Microenvironment.
LID - 10.3390/cells12192404 [doi]
LID - 2404
AB  - Non-small-cell lung cancer (NSCLC) remains one of the leading causes of death 
      worldwide. While NSCLCs possess antigens that can potentially elicit T cell 
      responses, defective tumor antigen presentation and T cell activation hinder host 
      anti-tumor immune responses. The NSCLC tumor microenvironment (TME) is composed 
      of cellular and soluble mediators that can promote or combat tumor growth. The 
      composition of the TME plays a critical role in promoting tumorigenesis and 
      dictating anti-tumor immune responses to immunotherapy. Dendritic cells (DCs) are 
      critical immune cells that activate anti-tumor T cell responses and sustain 
      effector responses. DC vaccination is a promising cellular immunotherapy that has 
      the potential to facilitate anti-tumor immune responses and transform the 
      composition of the NSCLC TME via tumor antigen presentation and cell-cell 
      communication. Here, we will review the features of the NSCLC TME with an 
      emphasis on the immune cell phenotypes that directly interact with DCs. 
      Additionally, we will summarize the major preclinical and clinical approaches for 
      DC vaccine generation and examine how effective DC vaccination can transform the 
      NSCLC TME toward a state of sustained anti-tumor immune signaling.
FAU - Abascal, Jensen
AU  - Abascal J
AD  - Division of Pulmonary and Critical Care, Department of Medicine, David Geffen 
      School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
FAU - Oh, Michael S
AU  - Oh MS
AD  - Division of Pulmonary and Critical Care, Department of Medicine, David Geffen 
      School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
FAU - Liclican, Elvira L
AU  - Liclican EL
AD  - Division of Pulmonary and Critical Care, Department of Medicine, David Geffen 
      School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
FAU - Dubinett, Steven M
AU  - Dubinett SM
AD  - Division of Pulmonary and Critical Care, Department of Medicine, David Geffen 
      School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
AD  - Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA 
      90073, USA.
AD  - Department of Molecular and Medical Pharmacology, David Geffen School of Medicine 
      at UCLA, Los Angeles, CA 90095-1690, USA.
AD  - Department of Pathology and Laboratory Medicine, David Geffen School of Medicine 
      at UCLA, Los Angeles, CA 90095-1690, USA.
AD  - Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095-1690, USA.
FAU - Salehi-Rad, Ramin
AU  - Salehi-Rad R
AD  - Division of Pulmonary and Critical Care, Department of Medicine, David Geffen 
      School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
AD  - Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA 
      90073, USA.
FAU - Liu, Bin
AU  - Liu B
AD  - Division of Pulmonary and Critical Care, Department of Medicine, David Geffen 
      School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
LA  - eng
GR  - IK2 BX006194/BX/BLRD VA/United States
GR  - T32 CA009120/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231004
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (Antigens, Neoplasm)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/metabolism
MH  - *Lung Neoplasms/metabolism
MH  - Tumor Microenvironment
MH  - Antigens, Neoplasm/metabolism
MH  - Vaccination
MH  - Dendritic Cells
PMC - PMC10571973
OTO - NOTNLM
OT  - DC
OT  - DC vaccination
OT  - NSCLC
OT  - TME
OT  - dendritic cell
OT  - immunotherapy
OT  - lung cancer
OT  - lung cancer vaccination
OT  - non-small-cell lung cancer
OT  - tumor microenvironment
OT  - tumor vaccination
COIS- S.M.D. serves on scientific advisory boards for LungLife AI, Thousand Oaks, CA 
      and Early Diagnostics, Inc. Los Angeles, CA, USA.
EDAT- 2023/10/13 12:42
MHDA- 2023/11/01 12:43
PMCR- 2023/10/04
CRDT- 2023/10/13 08:13
PHST- 2023/08/29 00:00 [received]
PHST- 2023/09/23 00:00 [revised]
PHST- 2023/10/02 00:00 [accepted]
PHST- 2023/11/01 12:43 [medline]
PHST- 2023/10/13 12:42 [pubmed]
PHST- 2023/10/13 08:13 [entrez]
PHST- 2023/10/04 00:00 [pmc-release]
AID - cells12192404 [pii]
AID - cells-12-02404 [pii]
AID - 10.3390/cells12192404 [doi]
PST - epublish
SO  - Cells. 2023 Oct 4;12(19):2404. doi: 10.3390/cells12192404.